NCT03189615

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Interventional, Open-label, Three-group, Single-dose Study Investigating the Pharmacokinetic Properties of Lu AF35700 in Subjects With Hepatic Impairment (Mild or Moderate) and in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of a single oral dose of Lu AF35700

Conditions

• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	Lu AF35700	Single oral dose of 10 mg Lu AF35700

Timeline

• Start date: 2017-05-14
• Primary completion: 2018-02-28
• Completion: 2018-04-23
• First posted: 2017-06-16
• Last updated: 2018-05-04

Locations

1 site across 1 country: Germany